Phase 2 N=42 Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Efficacy — 4; 18; 12; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Awareness and Self-Compassion Enhancing Narcolepsy Treatment
Narcolepsy · Narcolepsy Without Cataplexy · Narcolepsy With Cataplexy
Primary: Number of Participants Who Attended ≥ 80% of Sessions — 15; 13; 15 Participants
N/A N=2,673 Expanding the Click City Tobacco Prevention Program to Include E-cigarettes and Other Novel Tobacco Products
Tobacco Use
Primary: Change in Behavioral Intentions to Vape E-cigarettes — -.14; 0.0 score on a scale — p== .000
N/A N=110 Diagnostic Accuracy of Handheld vs Traditional Ultrasound
Image, Body
Primary: Diagnostic Accuracy — 53; 56 Participants
Phase 3 N=811 Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Colorectal Cancer
Primary: OS in Participants With Left-sided Tumors — 37.85; 34.30 Months
N/A N=83 Dual Focus Soft Contact Lens Wear Cessation Study
Myopia
Primary: Change in Spherical Equivalent Refractive Error (SERE) — -0.23; -0.21 D
Phase 4 N=18 Repeatability in Hyperpolarized 3-Helium With MRI
Radiation Exposure
Primary: Apparent Diffusion Coefficient (ADC) as a Function of Lung Inflation Levels. — 0.167; 0.175; 0.188 ADC (cm2/sec) — p=<0.001
N/A N=521 Pneumococcal Nasopharyngeal and Oropharyngeal Carriage in Adults
Preference, Patient
Primary: Prevalence — 16 Participants
Phase 2 N=55 A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
Crohn Disease
Primary: Adverse Events — 43 Participants
Phase 2 N=154 Intravenous Ketamine Plus Neurocognitive Training for Depression
Depression
Primary: Montgomery Asberg Depression Scale — 19.72; 22.87; 23.51 score on a scale — p=.0004
Phase 2 N=30 Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
GVHD, Chronic
Primary: Overall Response Rate (ORR) — 73.3 percentage of participants
N/A N=101 Efficacy of T2259 in DED
Dry Eye Syndromes
Primary: Surface Ocular Staining With Fluorescein (With Oxford Scale - Ranges : 0-15) — -1.45; -1.79 score on a scale
Phase 2 N=248 A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
Erosive Esophagitis
Primary: Number of Patients With Esophageal Mucosa Healing — 28; 28; 32; 18 Participants
N/A N=105 Mopati: A Pilot Hiv Treatment Partner Intervention In Botswana
HIV
Primary: Viral Suppression of Patient Participants — 12; 13 Participants — p=0.49
Phase 2 N=51 A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19
COVID-19
Primary: Incidence of Hospitalization for COVID-19 — 0 Participants